- Home
- ETON vs LXRX Comparison
ETON vs LXRX Comparison
Compare ETON & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- LXRX
- Stock Information
- Founded
- ETON 2017
- LXRX 1995
- Country
- ETON United States
- LXRX United States
- Employees
- ETON N/A
- LXRX N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- LXRX Health Care
- Exchange
- ETON Nasdaq
- LXRX Nasdaq
- Market Cap
- ETON 388.3M
- LXRX 428.8M
- IPO Year
- ETON 2018
- LXRX 2000
- Fundamental
- Price
- ETON $17.68
- LXRX $1.09
- Analyst Decision
- ETON Strong Buy
- LXRX Buy
- Analyst Count
- ETON 3
- LXRX 5
- Target Price
- ETON $29.67
- LXRX $3.23
- AVG Volume (30 Days)
- ETON 206.2K
- LXRX 1.6M
- Earning Date
- ETON 11-11-2025
- LXRX 11-11-2025
- Dividend Yield
- ETON N/A
- LXRX N/A
- EPS Growth
- ETON N/A
- LXRX N/A
- EPS
- ETON N/A
- LXRX N/A
- Revenue
- ETON $58,181,000.00
- LXRX $58,432,000.00
- Revenue This Year
- ETON $105.25
- LXRX N/A
- Revenue Next Year
- ETON $40.84
- LXRX N/A
- P/E Ratio
- ETON N/A
- LXRX N/A
- Revenue Growth
- ETON 85.40
- LXRX 1504.83
- 52 Week Low
- ETON $5.35
- LXRX $0.28
- 52 Week High
- ETON $21.48
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- ETON 59.16
- LXRX 47.78
- Support Level
- ETON $17.24
- LXRX $1.03
- Resistance Level
- ETON $18.52
- LXRX $1.19
- Average True Range (ATR)
- ETON 0.66
- LXRX 0.06
- MACD
- ETON -0.07
- LXRX -0.00
- Stochastic Oscillator
- ETON 54.10
- LXRX 35.29
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.